Establishment Labs Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
9analysts covering
FY Revenue (est.)
$270.2Mnext fiscal year
FY EPS (est.)
-$1.10next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| Q4 and Full Year 2026 Earnings Release | 24 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Total Revenue Growth Quarterly4,470.0%Target: At least 25% growth for FY 2026 and FY 2027
U.S. Motiva Sales Quarterly19.6MTarget: Continued sequential and year-over-year expansion following FDA approval
Minimally Invasive Platform Revenue Quarterly9.1MTarget: Exceed $35 million for FY 2026
Gross Margin Quarterly7,070.0%Target: 71.2% to 72.2% for FY 2026
Adjusted EBITDA Quarterly1.2MTarget: Positive adjusted EBITDA in each quarter of 2026
Watch Items
- U.S. Commercial Launch Execution
- Operating Expense ControlTrigger: Full-year operating expenses exceeding the guided range of $195 million to $200 million
- Free Cash Flow PositivityTrigger: Failure to achieve positive free cash flow in the second half of 2026
Research as of 20 Jun 2026